Covance, Parexel Will Pursue Smaller Acquisitions Following Merger Failure

Covance has approximately $750 mil. in acquisition resources readily available to continue its consolidation and diversification efforts in the CRO and pharmaceutical support areas after the breakup of the Parexel purchase.